Dr. Advani Discusses CD30 as a Target in ALCL

Ranjana Advani, MD
Published: Thursday, Apr 18, 2013

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses CD30 as a target and the use of brentuximab vedotin in anaplastic large-cell lymphoma (ALCL).

The expression of CD30 in ALCL makes it attractive to study for targeted therapies, Advani says. The antibody drug conjugate brentuximab vedotin targets CD30 and is approved by the FDA for relapsed or refractory ALCL. The agent has demonstrated an overall response rate in excess of 80%, including some extremely durable responses.

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses CD30 as a target and the use of brentuximab vedotin in anaplastic large-cell lymphoma (ALCL).

The expression of CD30 in ALCL makes it attractive to study for targeted therapies, Advani says. The antibody drug conjugate brentuximab vedotin targets CD30 and is approved by the FDA for relapsed or refractory ALCL. The agent has demonstrated an overall response rate in excess of 80%, including some extremely durable responses.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AMLMay 31, 20181.0
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Publication Bottom Border
Border Publication
x